Proton Pump Inhibitors (PPI) as a New Strategy for Therapy in Sepsis: Clinical Trial to Reduce Severity of Organ Failure and in Vitro Experiments to Search Specific Hallmarks in Monocytes From Septic Patients and to Characterize the Mechanism of Action of PPI
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 300
- Locations
- 17
- Primary Endpoint
- SOFA score reduction
Study Overview
Brief Summary
Sepsis is a severe disease with a high mortality rate and lack of efficacious therapies. Proton pump inhibitors (PPI) are drugs widely used to inhibit acid secretion by gastric cells and with a high safety profile. Carta and Rubartelli (IRCCS San Martino - Genova) have recently reported that PPI, such as esomeprazole, inhibit TNF-alfa and IL-1ß secretion. Moreover, they showed that a single administration of PPI protects mice from endotoxic shock with no adverse effects. PPI-SEPSIS is a randomized, double blind, controlled against placebo clinical trial to test if high-doses esomeprazole in septic patients reduces the severity of organs failure.
In parallel, the investigators will evaluate ex vivo in monocytes from septic patients: redox state and response to inflammatory stimuli; ATP release; metabolic changes and pH; cytokine production; the effects of PPI on these parameters.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years old
- •Admitted to intensive care unit or emergency department
- •Sepsis or septic shock
- •Able to express informed consent. For unconscious patients, current laws will be applied as requested by Ethical Committee.
- •Exclusion Criteria
- •Able to express informed consent and deny it
- •Known allergy or intolerance to study drug
- •Little chance of survival, as defined by a SAPS II score more than 65 point
- •Concomitant acquired immunodeficiency syndrome
- •On immunosuppressant or long-term corticosteroid therapy
- •Receiving lifesaving drugs known to have a strong interference with esomeprazole
- •Sepsis or septic shock since over 36 hours
- •Severe hepatic dysfunction
- •Pregnant or breastfeeding
Exclusion Criteria
- Not provided
Arms & Interventions
Esomeprazole
Patients randomized to Esomeprazole Group will receive a bolus of 160 mg of esomeprazole (diluted in 100 ml of 0.9% sodium chloride for intravenous use and administered over 60 minutes) and an intravenous infusion of 12 mg/hr (diluted in 0.9% sodium chloride at a concentration of 8 mg/ml will be injected at a rate of 1.5 ml/hr) for 72 hours .
Intervention: Esomeprazole (Drug)
Placebo
Patients randomized to Placebo Group will receive a bolus of 100 ml of 0.9% sodium chloride for intravenous use administered over 60 minutes with no active principle and an intravenous infusion of 0.9% sodium chloride at a rate of 1.5 ml/hr with no active principle for 72 hours .
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
SOFA score reduction
Time Frame: Days 1-28
SOFA (sequential organ failure assessment) score is used to track a person's status during the stay in an intensive care unit to determine the extent of a person's organ function or rate of failure. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems which are added up. Each score ranges from 0 to 4. SOFA score ranges from 0 (better outcome) to 24 points (worse outcome).
Secondary Outcomes
- Antibiotic-free days(Day 28)
- Adjusted ICU-free days(Day 28)
- Mortality(Day 28, 60 and 90)
- Single organ failure severity(Days 1-28)
Investigators
Giovanni Landoni
MD, Associate Professor
Università Vita-Salute San Raffaele